Importantly, in recent years antibodies (e.g., siltuximab) targeting the IL-6/JAK/STAT3 pathway have been tested as monotherapy or in combination with cytotoxic drugs in various clinical trials for treatment of cancers, including prostate cancer (119, 140–142). This evidence concerns the gene IL6 and prostate cancer.